Internal Medicine, Nephrology · McAllen, TX
NPI
1669786042
Since 2010
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
110 E. Savannah Ave., Bldg. C Suite 201
McAllen, TX, 78503
Phone (956) 800-1820
Groups this clinician bills Medicare through
Medicare paid, 2024
$349K
2,630 services
Medicare patients, 2024
340
Average age 68
Drug cost, 2024
$1.4M
2,876 prescriptions
Company payments, 2025
$2,445
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nyan W Phyo was code 99233 (hospital e&m - subsequent), 937 times for 169 patients. In total Nyan W Phyo billed 2,630 services in 14 codes, and Medicare paid $349K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-03-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 937 | 169 | $89.77 | $84K |
| 90960 ESRD Related Services (not dialysis) | Office | 593 | 92 | $265.80 | $158K |
| 99232 Hospital E&M - Subsequent | Facility | 365 | 107 | $59.37 | $22K |
| 99215 Office E&M - Established | Office | 179 | 80 | $92.70 | $17K |
| 99222 Hospital E&M - Initial | Facility | 123 | 66 | $97.78 | $12K |
| 99223 Hospital E&M - Initial | Facility | 93 | 86 | $131.25 | $12K |
| 90966 ESRD Related Services (not dialysis) | Office | 74 | 17 | $221.79 | $16K |
| 99214 Office E&M - Established | Office | 71 | 53 | $79.87 | $5,671 |
| 90937 Hemodialysis | Facility | 58 | 37 | $77.21 | $4,478 |
| 90935 Hemodialysis | Facility | 52 | 33 | $52.63 | $2,737 |
| 90961 ESRD Related Services (not dialysis) | Office | 50 | 32 | $221.71 | $11K |
| 99204 Office E&M - New | Office | 27 | 27 | $99.38 | $2,683 |
By year: 2022 $329K for 2,932 services; 2023 $359K for 2,883 services; 2024 $349K for 2,630 services.
Medicare prescription drug claims, 2024
In 2024, the drug Nyan W Phyo prescribed most often to Medicare patients was Sevelamer Carbonate, with 259 prescriptions and refills. In total Nyan W Phyo wrote 2,876 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Sevelamer Carbonate Generic | 259 | 463 | 96 | $75K |
| Furosemide Generic | 225 | 447 | 100 | $1,146 |
| Velphoro Sucroferric Oxyhydroxide | 165 | 172 | 45 | $422K |
| Lokelma Sodium Zirconium Cyclosilicate | 125 | 149 | 54 | $91K |
| Midodrine Hcl Generic | 102 | 162 | 38 | $4,824 |
| Prosol Parenteral Amino Acid 20% No.1 | 93 | 93 | Under 11 | $14K |
| Allopurinol Generic | 91 | 214 | 33 | $622 |
| Nifedipine Er Nifedipine | 88 | 200 | 33 | $3,235 |
| Bumetanide Generic | 77 | 161 | 33 | $3,838 |
| Clinisol Parenteral Amino Acid 15% No.5 | 73 | 73 | Under 11 | $14K |
| Veltassa Patiromer Calcium Sorbitex | 70 | 96 | 28 | $83K |
| Cefdinir Generic | 69 | 69 | 58 | $821 |
| Hydralazine Hcl Generic | 64 | 148 | 31 | $866 |
| Amlodipine Besylate Generic | 63 | 167 | 32 | $428 |
| Losartan Potassium Generic | 57 | 158 | 30 | $556 |
Brand drugs: - claims; generic drugs: 2,018 claims; opioid claims: 28.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nyan W Phyo $2,445 ($2,445 in general payments such as food, travel and fees) from 13 companies. The largest payer was Vifor Pharma, Inc. with $520.
| Company | Payments | Amount |
|---|---|---|
| Vifor Pharma, Inc. | 25 | $520 |
| Novo Nordisk Inc NVO | 11 | $305 |
| Akebia Therapeutics Inc AKBA | 14 | $275 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 13 | $239 |
| Amgen Inc. AMGN | 13 | $231 |
| Fresenius USA Marketing, Inc. | 12 | $220 |
| Calliditas Therapeutics US Inc. | 12 | $216 |
| Pharmacosmos Therapeutics Inc. | 1 | $125 |
| AstraZeneca Pharmaceuticals LP AZN | 6 | $117 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $81.92 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.